Pranav Harshad Patel

Mr. Pranav Harshad Patel

Royal Marsden NHS Foundation Trust, London, City of London, UK
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017
Verified
Conference Paper
Closed access
PPPranav Harshad Patel
Pranav Harshad Patel
ASAshish Shandilya
Ashish Shandilya
Dipankar DebDipankar Deb
Dipankar Deb
Comparative study of several forecasting schemes is performed on a dataset of a wind farm. The paper presents a generalized economy optimization of the power generated from a wind farm and batteries. These wind farms are coupled to the electrical grid to supply amount of power agreed upon a priori, irrespective of the associated penalty due to inherent randomness in the wind. The solution is to have an optimized wind forecasting technique such that the deficit power is supplied by batteries and during period of surplus power, the additional power is stored in the batteries. Economic considerations include a consumption factor that evaluates the depletion of battery life and assigns a dollar value to it.

1 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NPNikhil Manish Patel
Nikhil Manish Patel
GGGeorgios Geropoulos
Georgios Geropoulos
PPPranav Harshad Patel
Pranav Harshad Patel
RBRicky H Bhogal
Ricky H Bhogal
KHKevin Harrington
Kevin Harrington
SKSacheen Kumar
Sacheen Kumar
Survival in oesophago-gastric cancer (OGC) is poor due to early diagnostic challenges. Non-invasive risk stratification may identify susceptible patients with pre-malignant or benign disease. Following diagnostic confirmation with endoscopic biopsy, early OGC may be treated sooner. Mucins are transmembrane glycoproteins implicated in OGC with potential use as biomarkers of malignant transformation. This systematic review defines the role of mucins in OGC diagnosis. A literature search of MEDLINE, Web of Science, Embase and Cochrane databases was performed following PRISMA protocols for studies published January 1960–December 2022. Demographic data and data on mucin sampling and analysis methods were extracted. The review included 124 studies (n = 11,386 patients). Gastric adenocarcinoma (GAc) was the commonest OG malignancy (n = 101) followed by oesophageal adenocarcinoma (OAc, n = 24) and squamous cell carcinoma (OSqCc, n = 10). Mucins MUC1, MUC2, MUC5AC and MUC6 were the most frequently implicated. High MUC1 expression correlated with poorer prognosis and metastases in OSqCc. MUC2 expression decreases during progression from healthy mucosa to OAc, causing reduced protection from gastric acid. MUC5AC was upregulated, and MUC6 downregulated in GAc. Mucin expression varies in OGC; changes may be epigenetic or mutational. Profiling upper GI mucin expression in OGC, with pre-malignant, benign and healthy controls may identify potential early diagnostic biomarkers.

1 September 2012 in JRSM Short Reports
Verified
Journal Article
Open access
PPPranav Harshad Patel
Pranav Harshad Patel
ASAlistair Ap Slesser
Alistair Ap Slesser
PIPraveena Idaikkadar
Praveena Idaikkadar
IKIoanna Kostourou
Ioanna Kostourou
RAReda W Awad
Reda W Awad

26 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RGRachna Gorbudhun
Rachna Gorbudhun
PPPranav Harshad Patel
Pranav Harshad Patel
EHEve Hopping
Eve Hopping
JDJoseph Doyle
Joseph Doyle
GGGeorgios Geropoulos
Georgios Geropoulos
RBRicky H Bhogal
Ricky H Bhogal
Background: Patients with borderline-resectable pancreatic ductal adenocarcinoma (BR-PDAC) have historically poor survival, even after curative pancreatic resection and adjuvant chemotherapy. Emerging evidence suggests that neoadjuvant chemoradiation (NCR) improves R0 resection rates in BR-PDAC patients. We evaluated the R0 resection rate, disease-free survival (DFS) and overall survival (OS) in our patients who underwent NCR for BR-PDAC at our institution. Methods: All patients who underwent NCR for BR-PDAC from January 2010 to March 2020 were included in the study. The patients received a variety of NCR regimens during the study period, and in patients with radiological evidence of tumour stability or regression, pancreatic resection was performed. The primary endpoint was the OS, and the secondary endpoints included patient morbidity, the R0 resection rate, histological parameters and the DFS. Results: The study included 29 patients (16 men and 13 women), with a median age of 65 years (range 46–74 years). Of these 29 patients, 17 received FOLFIRINOX and 12 received gemcitabine (GEM)-based NCR regimens. All patients received chemoradiation at the end of chemotherapy (range 45–56 Gy). R0 resection was achieved in 75% of the patients, with a higher rate noted in the FOLFIRINOX group. The median DFS was 22 months for the whole cohort but higher in the FOLFIRINOX group (34 months). The median OS for the cohort was 29 months, with a higher median OS noted for the FOLFIRINOX cohort versus the GEM cohort (42 versus 28 months). Conclusion: NCR, particularly FOLFIRINOX-based treatment, for BR-PDAC results in higher rates of R0 resection and an increased median DFS and OS, supporting its continued use in this patient group.

25 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
PPPranav Harshad Patel
Pranav Harshad Patel
NPNikhil Manish Patel
Nikhil Manish Patel
JDJoseph Doyle
Joseph Doyle
HPHina K. Ba Patel
Hina K. Ba Patel
YAYousef Bm. B.Ch Alhasan
Yousef Bm. B.Ch Alhasan
WAWilliam H. Allum
William H. Allum
Background: Radical surgery for esophageal cancer requires macroscopic and microscopic clearance of all malignant tissue. A critical element of the procedure is achieving a negative circumferential margin (CRM) to minimize local recurrence. The utility of minimally invasive surgery poses challenges in replicating techniques developed in open surgery, particularly for hiatal dissection in esophago-gastrectomy. In this study, the technical approach and clinical and oncological outcomes for open and laparoscopic esophago-gastrectomy are described with particular reference to CRM involvement. Materials and methods: This cohort study included all patients undergoing either open or laparoscopic esophago-gastrectomy between January 2004 and June 2022 in a single tertiary center. A standard surgical technique for hiatal dissection of the esophago-gastric junction developed in open surgery was adapted for a laparoscopic approach. Clinical parameters, length of stay (LOS), postoperative complications, and mortality data were collected and analyzed by a Mann–Whitney U or Fisher’s exact method. Results: Overall 447 patients underwent an esophago-gastrectomy in the study with 219 open and 228 laparoscopic procedures. The CRM involvement was 18.8% in open surgery and 13.6% in laparoscopic surgery. The 90-day-mortality for open surgery was 4.1 compared with 2.2% for laparoscopic procedures. Median Intensive care unit (ITU), inpatient LOS and 30-day readmission rates were shorter for laparoscopic compared with open esophago-gastrectomy (ITU: 5 versus 8 days, P=0.0004; LOS: 14 versus 20 days, P=0.022; 30-day re-admission 7.46 versus 10.50%). Postoperative complication rates were comparable across both cohorts. The rates of starting adjuvant chemotherapy were 51.8 after open and 74.4% in laparoscopic esophago-gastrectomy. Conclusion: This study presents a standardized surgical approach to hiatal dissection for esophageal cancer. The authors present equivalence between open and laparoscopic esophago-gastrectomy in clinical, oncological, and survival outcomes with similar rates of CRM involvement. The authors also observe a significantly shorter hospital length of stay with the minimally invasive approach.

5 August 2024 in Annals of Surgery
Verified
Journal Article
Open access
MSMarcel André Schneider
Marcel André Schneider
JKJeesun Kim
Jeesun Kim
FBFelix Berlth
Felix Berlth
YSYutaka Sugita
Yutaka Sugita
PGP.P. Grimminger
P.P. Grimminger
CGChristian A. Gutschow
Christian A. Gutschow
Objective/Background: Various anastomotic and reconstruction techniques are used for minimally invasive total (miTG) and distal gastrectomy (miDG). Their effects on postoperative morbidity have not been extensively studied. Methods: MiTG and miDG patients were selected from 9356 oncological gastrectomies performed in 2017–2021 in 43 centers. Endpoints included anastomotic leakage (AL) rate and postoperative morbidity tested by multivariable analysis. Results: Three major anastomotic techniques [circular stapled (CS); linear stapled (LS); and hand sewn (HS)], and 3 major bowel reconstruction types [Roux (RX); Billroth I (BI); Billroth II (BII)] were identified in miTG (n=878) and miDG (n=3334). Postoperative complications, including AL (5.2% vs 1.1%), overall (28.7% vs 16.3%), and major morbidity (15.7% vs 8.2%), as well as 90-day mortality (1.6% vs 0.5%) were higher after miTG compared with miDG. After miTG, the AL rate was higher after CS (4.3%) and HS (7.9%) compared with LS (3.4%). Similarly, major complications (LS: 9.7%, CS: 16.2%, and HS: 12.7%) were lowest after LS. Multivariate analysis confirmed anastomotic technique as a predictive factor for AL, overall, and major complications. In miDG, AL rate (BI: 1.4%, BII 0.8%, and RX 1.2%), overall (BI: 14.5%, BII: 15.0%, and RX: 18.7%), and major morbidity (BI: 7.9%, BII: 9.1%, and RX: 7.2%), and mortality (BI: 0%, BII: 0.1%, and RY: 1.1%%) were not affected by bowel reconstruction. Conclusions: In oncologically suitable situations, miDG should be preferred to miTG, as postoperative morbidity is significantly lower. LS should be a preferred anastomotic technique for miTG in Western Centers. Conversely, bowel reconstruction in DG may be chosen according to the surgeon’s preference.